<DOC>
	<DOCNO>NCT01927055</DOCNO>
	<brief_summary>Evaluate clinical efficacy safety droxidopa versus placebo 17 week ( maximum ) treatment period patient symptomatic NOH .</brief_summary>
	<brief_title>A Clinical Study Patients With Symptomatic NOH Assess Sustained Effects Droxidopa Therapy</brief_title>
	<detailed_description>This multi-center , multi-national , randomize , parallel-group , placebo-controlled , double-blind study 17 week ( maximum ) treatment period consist initial , open-label dose titration ( 2 week ) , follow washout period ( 3 week ) , follow 12 week treatment period stable dose .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Hypotension</mesh_term>
	<mesh_term>Multiple System Atrophy</mesh_term>
	<mesh_term>Shy-Drager Syndrome</mesh_term>
	<mesh_term>Pure Autonomic Failure</mesh_term>
	<mesh_term>Hypotension , Orthostatic</mesh_term>
	<mesh_term>Autonomic Nervous System Diseases</mesh_term>
	<mesh_term>Droxidopa</mesh_term>
	<criteria>1 . 18 year old ambulatory ( define able walk least 10 meter ) ; 2 . Clinical diagnosis symptomatic orthostatic hypotension associate Primary Autonomic Failure ( PD , MSA PAF ) , Dopamine Beta Hydroxylase Deficiency ; 3 . At Baseline visit ( Visit 2 ) , patient must demonstrate : 1. score least 4 great Orthostatic Hypotension Symptom Assessment ( OHSA ) Item # 1 ; 2. fall least 20 mmHg systolic blood pressure , within 3 minute stand ; 4 . Provide write informed consent participate study understand may withdraw consent time without prejudice future medical care ; 1 . Score 23 low minimental state examination ( MMSE ) ; 2 . Concomitant use vasoconstricting agent purpose increase blood pressure ; 1 . Patients take vasoconstricting agent ephedrine , dihydroergotamine , midodrine must stop take drug least 2 day 5 halflives ( whichever longer ) prior baseline visit ( Visit 2 ) throughout duration study ; 3 . Known suspected alcohol substance abuse within past 12 month ( DSMIV definition alcohol substance abuse ) ; 4 . Women pregnant breastfeeding ; 5 . Women child bear potential ( WOCP ) use least one method contraception partner ; 6 . Male patient sexually active woman child bear potential ( WOCP ) use least one method contraception ; 7 . Untreated close angle glaucoma ; 8 . Diagnosis hypertension require treatment antihypertensive medication ( shortacting antihypertensive treat nocturnal supine HTN allow study ) Any significant uncontrolled cardiac arrhythmia ; 9 . History myocardial infarction , within past 2 year ; 10 . Current unstable angina ; 11 . Congestive heart failure ( NYHA Class 3 4 ) ; 12 . History cancer within past 2 year successfully treat , nonmetastatic cutaneous squamous cell basal cell carcinoma cervical cancer situ ; 13 . Gastrointestinal condition may affect absorption study drug ( e.g . ulcerative colitis , gastric bypass ) ; 14 . Any major surgical procedure within 30 day prior Baseline visit ( Visit 2 ) ; 15 . Previously treat droxidopa within 30 day prior Baseline visit ( Visit 2 ) ; 16 . Currently receive investigational drug receive investigational drug within 30 day prior Baseline visit ( Visit 2 ) ; 17 . Any condition laboratory test result , Investigator 's judgment , might result increase risk patient , would affect participation study ; 18 . The Investigator ability exclude patient reason feel subject good candidate study able follow study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>NOH</keyword>
	<keyword>OH</keyword>
	<keyword>PD</keyword>
	<keyword>MSA</keyword>
	<keyword>PAF</keyword>
	<keyword>DBH</keyword>
</DOC>